Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan O'Brien

Showing results (1-10 of 643) with videos related to

Pageof 65
Sort By:
Clinical Advances in Hematology & Oncology : H&O|July 13, 2006
Practical applications of measuring and monitoring MRD in patients with CLLSusan O'Brien
Clinical Advances in Hematology & Oncology : H&O|April 10, 2015
The changing landscape in CLLSusan O'Brien
Clinical Advances in Hematology & Oncology : H&O|June 27, 2008
Incorporating prognostic factors into treatment decisionsSusan O'Brien
Clinical Advances in Hematology & Oncology : H&O|July 21, 2023
Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: leukemia and lymphomaSusan O'Brien
Current Hematologic Malignancy Reports|December 29, 2010
Survival advantage in CLL with frontline FCR therapySusan O'Brien
Hematology. American Society of Hematology. Education Program|December 17, 2008
New agents in the treatment of CLLSusan O'Brien
The Lancet. Haematology|February 7, 2018
Rituximab maintenance is efficacious, but is it useful?Susan O'Brien
Journal of the National Comprehensive Cancer Network : JNCCN|October 3, 2009
Chronic myelogenous leukemia clinical practice guidelines in oncologySusan O'Brien,
Oncology (Williston Park, N.Y.)|April 12, 2017
Commentary (O'Brien): The Biology and Treatment of Chronic Myelogenous LeukemiaSusan O'Brien
Clinical Advances in Hematology & Oncology : H&O|January 11, 2008
Expert perspectives on advances in hematologic malignanciesSusan O'Brien
Pageof 65

Showing results (1-10 of 643) with videos related to

Sort By:
Pageof 65
Clinical Advances in Hematology & Oncology : H&O|July 13, 2006
Practical applications of measuring and monitoring MRD in patients with CLLSusan O'Brien
Clinical Advances in Hematology & Oncology : H&O|April 10, 2015
The changing landscape in CLLSusan O'Brien
Clinical Advances in Hematology & Oncology : H&O|June 27, 2008
Incorporating prognostic factors into treatment decisionsSusan O'Brien
Clinical Advances in Hematology & Oncology : H&O|July 21, 2023
Highlights from the 2023 American Society of Clinical Oncology Annual Meeting: leukemia and lymphomaSusan O'Brien
Current Hematologic Malignancy Reports|December 29, 2010
Survival advantage in CLL with frontline FCR therapySusan O'Brien
Hematology. American Society of Hematology. Education Program|December 17, 2008
New agents in the treatment of CLLSusan O'Brien
The Lancet. Haematology|February 7, 2018
Rituximab maintenance is efficacious, but is it useful?Susan O'Brien
Journal of the National Comprehensive Cancer Network : JNCCN|October 3, 2009
Chronic myelogenous leukemia clinical practice guidelines in oncologySusan O'Brien,
Oncology (Williston Park, N.Y.)|April 12, 2017
Commentary (O'Brien): The Biology and Treatment of Chronic Myelogenous LeukemiaSusan O'Brien
Clinical Advances in Hematology & Oncology : H&O|January 11, 2008
Expert perspectives on advances in hematologic malignanciesSusan O'Brien
Pageof 65